Huzhou ZhanShu Biotechnology

Zhanshu Biotech is a clinical-stage biopharmaceutical company based in Huzhou, China, focused on developing innovative small molecule drugs targeting deubiquitinating enzymes (DUBs). The company's lead program, ZS-01, is a highly selective USP1 inhibitor currently in Phase 1 clinical development for patients with advanced solid tumors, particularly those exhibiting homologous recombination deficiency (HRD). Zhanshu Biotech utilizes a proprietary drug discovery platform to identify novel DUB inhibitors, aiming to address unmet medical needs in oncology. The company has secured significant funding from leading investors such as Legend Capital and Northern Light Venture Capital to advance its pipeline of first-in-class and best-in-class therapies. With a strong focus on the ubiquitin-proteasome system, Zhanshu Biotech is positioned as a pioneer in the DUB-targeted therapeutic space in China.